Medicine & Life Sciences

1. Primary Myelofibrosis 100%
2. Systemic Mastocytosis 57%
3. Polycythemia Vera 44%
4. Mutation 40%
5. Essential Thrombocythemia 37%
6. Survival 27%
7. Mastocytosis 17%
8. Karyotype 16%
9. Eosinophilia 16%
10. Myelodysplastic Syndromes 16%
11. Imatinib Mesylate 14%
12. Mast Cells 14%
13. Janus Kinase Inhibitors 13%
14. Neoplasms 13%
15. N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide 12%
16. Therapeutics 11%
17. Cytogenetics 11%
18. Hypereosinophilic Syndrome 10%
19. Acute Myeloid Leukemia 9%
20. Bone Marrow 9%
21. Leukemia 9%
22. INCB018424 9%
23. Myeloproliferative Disorders 9%
24. Leukemia, Myelomonocytic, Chronic 9%
25. Fedratinib 9%
26. Janus Kinase 2 8%
27. Blast Crisis 8%
28. Hemoglobins 8%
29. Calreticulin 8%
30. Risk Management 7%
31. Thrombosis 7%
32. Cladribine 7%
33. Anemia 7%
34. venetoclax 6%
35. Platelet Count 6%
36. Alleles 6%
37. Scapharca 6%
38. Abnormal Karyotype 5%
39. Splenomegaly 5%
40. pomalidomide 5%
41. Chromosome Aberrations 5%
42. Mast-Cell Leukemia 5%
43. Leukemia, Neutrophilic, Chronic 5%